As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
CAR-T immunotherapy (Chimeric Antigen Receptor T-cell Therapy) refers to the transfer of genetic material encoding specific antigen recognition domains and T cell activation signals into T cells through gene modification technology. This enables T cells to recognize and bind to specific antigens present on the surface of tumor cells, activating them to directly kill tumor cells by releasing perforins, granzyme B, etc. Additionally, CAR-T cells recruit endogenous immune cells by releasing cytokines, enhancing the immune system's ability to target and kill tumor cells. This approach aims to treat tumors effectively and can also establish memory T cells for sustained, specific anti-tumor effects.